Nonprofit revives gene therapy programme abandoned when UK startup Bloomsbury closed

A nonprofit organisation has taken on the lead gene therapy programme of Bloomsbury Genetic Therapies after the UK startup shut down following dosing of just one patient.

Published · AI-drafted summary based on 1 public source
Illustration for rare disease story
Illustrative image — not from the source article.
Share

A nonprofit organisation has stepped in to continue the lead gene therapy programme developed by Bloomsbury Genetic Therapies, a UK-based startup that closed in 2025 after treating only a single patient. The revival, reported by Stat News on 27 October 2026, illustrates a growing pattern in rare-disease gene therapy: when commercial viability fails, academic institutions, patient foundations, and nonprofits increasingly absorb programmes that would otherwise be abandoned.

Bloomsbury's closure had left the patient community served by the programme without a clear path forward. The nonprofit acquisition preserves the clinical and manufacturing knowledge built up during the programme's development, avoiding the loss of years of work.

The case is relevant to researchers and genetic counsellors as an example of non-commercial gene therapy stewardship. It also connects thematically to broader sector questions about the sustainability of gene therapy business models for ultra-rare diseases — a topic also illustrated by the Pennsylvania Dutch community's independent gene therapy initiative reported by Genetic Current on 27 October 2026.

Specific details about the disease indication, the nonprofit's identity, and the timeline for continuation were not available in full from the paywalled Stat News report.

Sources

Read the original reporting — these are the public sources this summary draws from.

  1. Primary source Stat News · 2026-10-27
    STAT+: Nonprofit resurrects shelved gene therapy after startup shuts down

Tags

gene-therapy rare-disease nonprofit bloomsbury-genetic-therapies uk-genetics health-equity
Share

About Genetic Current

Educational summaries of public genetics news

Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.

Join the Evagene Alpha Waiting List